Zevra Therapeutics, Inc. Net Income (Loss) Available to Common Stockholders, Diluted
Zevra Therapeutics, Inc. (ZVRA) reported Net Income (Loss) Available to Common Stockholders, Diluted of $8.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted · last filed 2026-08-05
- Zevra Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-06-30 was $8.39M, a 87.64% decline year-over-year.
- Zevra Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2026-03-31 was $36.32M.
- Zevra Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-12-31 was $11.83M.
- Zevra Therapeutics, Inc. net income (loss) available to common stockholders, diluted for the quarter ending 2025-09-30 was -$544.00K.
- Zevra Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2025 was $77.58M.
- Zevra Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2024 was -$105.51M.
- Zevra Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2021 was -$62.92M.
- Zevra Therapeutics, Inc. net income (loss) available to common stockholders, diluted for fiscal 2020 was -$12.76M.
| Period end | Net Income (Loss) Available to Common Stockholders, Diluted 3 month | Net Income (Loss) Available to Common Stockholders, Diluted 3 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 6 month | Net Income (Loss) Available to Common Stockholders, Diluted 6 month as first filed | Net Income (Loss) Available to Common Stockholders, Diluted 9 month | Net Income (Loss) Available to Common Stockholders, Diluted 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $8.39M 10-Q · filed 2026-08-05 | $44.72M 10-Q · filed 2026-08-05 | $56.54M derived: sum of 3 quarters · filed 2026-08-05 | $56.00M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2026-03-31 | $36.32M 10-Q · filed 2026-05-06 | $48.15M derived: sum of 2 quarters · filed 2026-05-06 | $47.60M derived: sum of 3 quarters · filed 2026-05-06 | $115.51M derived: sum of 4 quarters · filed 2026-08-05 | ||
| 2025-12-31 | $11.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $11.29M derived: sum of 2 quarters · filed 2026-03-09 | $79.19M derived: sum of 3 quarters · filed 2026-08-05 | $77.58M 10-K · filed 2026-03-09 | ||
| 2025-09-30 | -$544.00K 10-Q · filed 2025-11-05 | $67.36M derived: sum of 2 quarters · filed 2026-08-05 | $65.75M 10-Q · filed 2025-11-05 | |||
| 2025-06-30 | $67.91M 10-Q · filed 2026-08-05 | $65.06M 10-Q · filed 2026-08-05 | ||||
| 2025-03-31 | -$3.10M 10-Q · filed 2026-05-06 | |||||
| 2024-12-31 | -$105.51M 10-K · filed 2026-03-09 | |||||
| 2021-12-31 | -$2.71M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$4.81M derived: sum of 2 quarters · filed 2022-03-31 | -$16.34M derived: sum of 3 quarters · filed 2022-03-31 | -$62.92M 10-K · filed 2022-03-31 | ||
| 2021-09-30 | -$2.09M 10-Q · filed 2021-11-10 | -$13.63M derived: sum of 2 quarters · filed 2021-11-10 | -$60.21M 10-Q · filed 2021-11-10 | -$65.06M derived: sum of 4 quarters · filed 2022-03-31 | ||
| 2021-06-30 | -$11.53M 10-Q · filed 2021-08-13 | -$58.44M 10-Q · filed 2021-08-13 | -$62.97M derived: sum of 3 quarters · filed 2022-03-31 | -$65.98M derived: sum of 4 quarters · filed 2022-03-31 | ||
| 2021-03-31 | -$46.58M derived: 10-K 12 month − 3 quarters · filed 2022-03-31 | -$51.44M derived: sum of 2 quarters · filed 2022-03-31 | -$54.45M derived: sum of 3 quarters · filed 2022-03-31 | -$53.61M derived: sum of 4 quarters · filed 2022-03-31 | ||
| 2020-12-31 | -$4.86M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-31 | -$7.87M derived: sum of 2 quarters · filed 2022-03-31 | -$7.03M derived: sum of 3 quarters · filed 2022-03-31 | -$12.76M 10-K · filed 2022-03-31 | ||
| 2020-09-30 | -$3.01M 10-Q · filed 2021-11-10 | -$2.17M derived: sum of 2 quarters · filed 2021-11-10 | -$7.90M 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $837.00K 10-Q · filed 2021-08-13 | $836.00K 10-Q · filed 2020-08-12 | -$4.97M 10-Q · filed 2021-08-13 | -$4.97M 10-Q · filed 2020-08-12 | ||
| 2019-09-30 | $1.91M 10-Q · filed 2020-10-30 | |||||
| 2018-06-30 | -$15.12M 10-Q · filed 2019-08-13 | |||||
| 2016-06-30 | -$9.00M 10-Q · filed 2017-08-10 | -$21.17M 10-Q · filed 2017-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |